Novel Aryl Sulfonium Modification on Vancomycin to Tackle MRSA and VRE In Vitro and In Vivo through Dual Enhanced Cell-Wall and Membrane Inhibition
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yuanyuan Xie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Vancomycin-Resistant Enterococci, Vancomycin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University.
Abstract (Originalsprache)
Gram-positive superbugs resistant to methicillin and vancomycin pose a severe threat to global public health, urgently demanding novel therapeutic strategies. Herein, we rationally designed and synthesized vancomycin derivatives modified with diverse aryl sulfonium moieties to reactivate its antibacterial potency. By optimizing the sulfonium-based SAR, we got derivatives 2-3 orders of magnitude more active in vitro than vancomycin. Subsequently, preliminary toxicity evaluations for the optimal derivative, 7e, indicated a favorable therapeutic index, while pharmacokinetic assays revealed its good properties, suggesting great drug-like potential. Notably, 7e showed extremely potent in vivo protection efficacy by only a single-dose treatment in the challenging methicillin-resistant Staphylococcus aureus and VRE lethal sepsis mice models. Moreover, two independent and synergistic mechanisms of action were uncovered: membrane perturbation and enhanced cell wall biosynthesis inhibition. These findings revealed the unknown role of sulfonium strategy in vitro and in vivo and positioned 7e as a promising candidate for future development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, no. 555 Zuchongzhi Rd, Pudong, Shanghai 201203, China.
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
- National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing 400038, China.
- Department of Endocrinology and Metabolism, Clinical Research Center, Shandong Provincial Key Medical and Health Discipline of Endocrinology, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Ch…
- Nanjing Cantech Microbial Technology Co. Ltd. no. 18, Zhilan Rd, Jiangning, Nanjing 211100, China.
ORCID-Profile: Feifei Chen, Dongliang Guan
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University
- Shandong Province Medical and Health Science and Technology Development Project
- Shanghai Post-doctoral Excellence Program
Zitieren
APA
Xie, Y., Wang, X., Chang, T., Chen, Z., Luo, Y., Zhang, J., Wang, H., Dong, J., Chen, F., Zhang, J., & Guan, D. (2025). Novel Aryl Sulfonium Modification on Vancomycin to Tackle MRSA and VRE In Vitro and In Vivo through Dual Enhanced Cell-Wall and Membrane Inhibition. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03028
Vancouver
Xie Y, Wang X, Chang T, Chen Z, Luo Y, Zhang J, et al. Novel Aryl Sulfonium Modification on Vancomycin to Tackle MRSA and VRE In Vitro and In Vivo through Dual Enhanced Cell-Wall and Membrane Inhibition. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03028
BibTeX
@article{Xie2025,
author = {Xie, Yuanyuan and Wang, Xiaowen and Chang, Taopeng and Chen, Zhifu and Luo, Youhong and Zhang, Jingwen and Wang, Hui and Dong, Jinhua and Chen, Feifei and Zhang, Jinyong and Guan, Dongliang},
title = {Novel Aryl Sulfonium Modification on Vancomycin to Tackle MRSA and VRE In Vitro and In Vivo through Dual Enhanced Cell-Wall and Membrane Inhibition},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03028}
}
EUVIMED